These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20068401)

  • 1. Guardians at the gate: patent protection of therapeutic monoclonal antibodies through product life cycle management--Part 3.
    McCabe KW; Calvo PA
    MAbs; 2009; 1(6):600-3. PubMed ID: 20068401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guardians at the gate: Biosimilar and patent reform legislation could fundamentally change the guards for therapeutic monoclonal antibodies--Part 2.
    McCabe KW
    MAbs; 2009; 1(5):417-21. PubMed ID: 20065635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1.
    McCabe KW
    MAbs; 2009; 1(4):382-4. PubMed ID: 20068400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic monoclonal antibody market.
    Ecker DM; Jones SD; Levine HL
    MAbs; 2015; 7(1):9-14. PubMed ID: 25529996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing antibody patent protection using epitope mapping information.
    Deng X; Storz U; Doranz BJ
    MAbs; 2018; 10(2):204-209. PubMed ID: 29120697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
    Jannuzzi AH; Vasconcellos AG; de Souza CG
    Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data mining patented antibody sequences.
    Krawczyk K; Buchanan A; Marcatili P
    MAbs; 2021; 13(1):1892366. PubMed ID: 33722161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different facets of competition in the pharmaceutical sector: preliminary findings of the European Commission's sector inquiry into pharmaceuticals.
    Borkowski F
    Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):1-5. PubMed ID: 20107914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody "gold rush".
    Maggon K
    Curr Med Chem; 2007; 14(18):1978-87. PubMed ID: 17691940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How drug life-cycle management patent strategies may impact formulary management.
    Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
    Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mAbs: a business perspective.
    Scolnik PA
    MAbs; 2009; 1(2):179-84. PubMed ID: 20061824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.